No Data
nanjing hicin pharmaceutical (300584.SZ): Currently not involved in AI pharmaceuticals
On November 6th, Ge Longhui reported that Nanjing Hicin Pharmaceutical (300584.SZ) stated on the investor interaction platform that the company is currently not involved in AI pharmaceuticals.
Nanjing Hicin Pharmaceutical (300584.SZ): Approval Notice for Supplementary Drug Application for the increased specification of Landedol Hydrochloride for Injection.
On November 6, Gelonhui reported that Nanjing Hicin Pharmaceutical (300584.SZ) recently received the Approval Notification for the supplementary application of Injection Landlelol Hydrochloride issued by the National Medical Products Administration (referred to as "NMPA"), approving the addition of 150mg specification on top of the approved 50mg specification, and considering it as passing the consistency evaluation.
Nanjing Hicin Pharmaceutical (300584.SZ): Voglibose tablets pass generic drug consistency evaluation
格隆汇October 28th | nanjing hicin pharmaceutical (300584.SZ) announced that the company recently received the "Drug Supplementary Application Approval Letter" issued by the National Medical Products Administration, and Voglibose tablets passed the generic drug quality and efficacy consistency evaluation. Voglibose tablets are oral hypoglycemic drugs, belonging to α-glucosidase inhibitors, which inhibit the α-glucosidase in the intestines that decompose disaccharides into monosaccharides, thereby delaying the digestion and absorption of sugar and improving postprandial hyperglycemia. The product is mainly used to improve postprandial hyperglycemia in diabetic patients (applicable to patients who have not achieved obvious effects with diet therapy and exercise therapy).
Haichen Pharmaceutical: Report for the third quarter of 2024
Nanjing Hicin Pharmaceutical (300584.SZ) plans to increase the capital of Anqing Huichen by 0.2 billion yuan and introduce 0.125 billion yuan of new investment.
Nanjing Hicin Pharmaceutical (300584.SZ) announced that its wholly-owned subsidiary, Anqing Huichen Technology Co., Ltd. ("Anqing Huichen...
Nanjing Hicin Pharmaceutical (300584.SZ): Wholly-owned subsidiary plans to increase capital and expand shares, The company waives some of its preferential subscription rights.
格隆汇October 11th | nanjing hicin pharmaceutical (300584.SZ) announced that its wholly-owned subsidiary Anqing Huichen plans to increase its capital and expand its shares. The registered capital will be increased from RMB 175 million to RMB 500 million, with an additional registered capital of 325 million, including Gu Yuqin (Chinese citizen) subscribing for an additional capital of RMB 18.5 million in monetary form, Qian Demin (Chinese citizen) subscribing for an additional capital of RMB 16.5 million in monetary form, Lu Shiping (Chinese citizen) subscribing for an additional capital of RMB 15 million in monetary form, and Jiang Jinyuan (Chinese citizen) subscribing for an additional capital of RMB 7,50.
Nanjing Hicin Pharmaceutical Co., Ltd.'s (SZSE:300584) 25% Share Price Plunge Could Signal Some Risk
No Data
